Cargando...
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin effect is significantly reduced or absent in individuals with T2DM. Thus, pharmacologic efforts to develop medications that mimi...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Healthcare Communications
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3124643/ https://ncbi.nlm.nih.gov/pubmed/22127767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-010-0013-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|